ArticleClinical & translational immunology2022
Impact of SARS-CoV-2 infection on vaccine-induced immune responses over time.
Article in Clinical & translational immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06784739 (COMMUNITY - the COVID-19 Immunity Study), which is not on this map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
COMMUNITY - the COVID-19 Immunity Study
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Risk assessment and antibody responses to SARS-CoV-2 in healthcare workers.Frontiers in public health · 2023Pooled it
- Article
- Impact of Prior COVID-19 Immunization and/or Prior Infection on Immune Responses and Clinical Outcomes.Viruses · 2024Review
- Longitudinal antibody dynamics after COVID-19 vaccine boosters based on prior infection status and booster doses.Scientific reports · 2024Article
- Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.Frontiers in immunology · 2024Article
- A Systematic Evaluation of the SARS-CoV-2 Vaccine-Induced Anti-S-RBD-Ig Response in a Population of Health Care Workers.Vaccines · 2023Article
- Article
- Article
- Article
- Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.Nature communications · 2023Article
- Seroprevalence and durability of antibody responses to AstraZeneca vaccination in Ugandans with prior mild or asymptomatic COVID-19: implications for vaccine policy.Frontiers in immunology · 2023Article
- Age-adjusted impact of prior COVID-19 on SARS-CoV-2 mRNA vaccine response.Frontiers in immunology · 2023Article
- Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Article
- Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022.Emerging infectious diseases · 2022Article
- Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.The Lancet. Infectious diseases · 2022Article
- Article
- Article
- T Cells Targeting SARS-CoV-2: By Infection, Vaccination, and Against Future Variants.Frontiers in medicine · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To determine the long-term impact of prior SARS-CoV-2 infection on immune responses after COVID-19 vaccination. Methods: Using longitudinally collected blood samples from the COMMUNITY study, we determined binding (WHO BAU mL Results: Vaccination with both vaccine platforms resulted in substantially enhanced T-cell responses, anti-spike IgG responses and neutralising antibodies effective against ten SARS-CoV-2 variants in SARS-CoV-2-recovered participants as compared to SARS-CoV-2-naïve participants. The enhanced immune responses sustained over 7 months following vaccination. Conclusion: These findings imply that prior SARS-CoV-2 infection should be taken into consideration when planning booster doses and design of current and future COVID-19 vaccine programmes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.